津巴布韦黑人队列的华法林药物遗传学：一项观察性前瞻性研究。
Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.
机构信息
Department of Genomic Medicine, African Institute of Biomedical Science & Technology, 911 Boronia Township, Beatrice, Zimbabwe.
Department of Biotechnology, Chinhoyi University of Technology, Private Bag 7724, Chinhoyi, Zimbabwe.
出版信息
Pharmacogenomics. 2023 Jul;24(10):529-538. doi: 10.2217/pgs-2023-0089. Epub 2023 Jul 12.
A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. , , and and c. 1639 G>A variations were observed in 62 study patients. Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on and only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants , and , and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort.
一项前瞻性观察性研究评估了在津巴布韦黑人患者中实施华法林剂量临床指南的可行性。在 62 例研究患者中观察到 、 、 和 以及 1639 G>A 变异。总体而言，62 例患者中有 39 例（62.90%）未接受临床药物遗传学实施联盟指南推荐的华法林起始剂量。美国 FDA 和荷兰药物遗传学工作组指南仅基于 和 ，因此，在未检测到这些变异的情况下，不太可能对本队列有用。另一方面，临床药物遗传学实施联盟指南对华法林剂量有特定的推荐，适用于在津巴布韦实施，并有助于优化研究队列中患者的华法林剂量。
Zotero 插件